All In Biotech

Drug Trial Radar · NCT06311656

A Study to Evaluate Safety, Tolerability of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

A Placebo-controlled, Phase 1, Participant- and Investigator-blinded, Single- and Multiple- Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY4100511 (DC-853) in Healthy Asian and Non-Asian Participants

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

69

Actual

Start

Mar 19, 2024

Primary completion

Oct 4, 2024

Study completion Oct 4, 2024

Sponsor

Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to assess the safety and tolerability of LY4100511 (DC-853) after single and multiple dose administrations in healthy asian participants and non-Asian participants. Part A consists of 2 groups and Part B, C, and D include optional groups.

Conditions

  • Healthy

Interventions

  • LY4100511 (DC-853)Drug

    Administered orally fasted

  • LY4100511 (DC-853)Drug

    Administered orally fasted.

  • LY4100511 (DC-853)Drug

    Administered orally fed and fasted.

  • LY4100511 (DC-853)Drug

    Administered orally fed and fasted.

  • PlaceboDrug

    Administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with one or more Treatment Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs)Time frame: Baseline up to 47 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Altasciences Clinical Los Angeles, Inc

    Cypress, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.